Cotner Cody E, O'Donnell Elizabeth
Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Harvard Medical School, Boston, MA 02115, USA.
Life (Basel). 2024 Jul 19;14(7):896. doi: 10.3390/life14070896.
Multi-cancer detection (MCD) tests are blood-based assays that screen for multiple cancers concurrently and offer a promising approach to improve early cancer detection and screening uptake. To date, there have been two prospective interventional studies evaluating MCD tests as a screening tool in human subjects. No MCD tests are currently approved by the FDA, but there is one commercially available MCD test. Ongoing trials continue to assess the efficacy, safety, and cost implications of MCD tests. In this review, we discuss the performance of CancerSEEK and Galleri, two leading MCD platforms, and discuss the clinical consideration for the broader application of this new technology.
多癌检测（MCD）测试是基于血液的检测方法，可同时筛查多种癌症，并为改善早期癌症检测和筛查接受度提供了一种有前景的方法。迄今为止，已有两项前瞻性干预研究评估了MCD测试作为人类受试者筛查工具的效果。目前美国食品药品监督管理局（FDA）尚未批准任何MCD测试，但有一种MCD测试已投入商业使用。正在进行的试验继续评估MCD测试的疗效、安全性和成本影响。在本综述中，我们讨论了两个领先的MCD平台CancerSEEK和Galleri的性能，并讨论了这项新技术更广泛应用的临床考量。
